Johnson & Johnson’s RYBREVANT® Shows Promising Results in Lung Cancer Study
RYBREVANT®Johnson’s with chemotherapy shows improved survival outcomes for EGFR-mutated NSCLC patients in Johnson & Johnson’s Phase 3 MARIPOSA-2 study.
RYBREVANT®Johnson’s with chemotherapy shows improved survival outcomes for EGFR-mutated NSCLC patients in Johnson & Johnson’s Phase 3 MARIPOSA-2 study.
Protect your family from rising Eastern Equine Encephalitis (EEE) cases with expert tips on mosquito prevention. Stay informed on effective safety measures.
America’s declining birthrate has become a vital issue in the 2024 election, with both parties offering policies to boost family growth and economic stability.
A new study reveals that long-term exposure to air pollution and unhealthy lifestyle choices significantly increase the risk of developing NAFLD.
Grit Biotechnology secures FDA approval for GT201, a cutting-edge cancer therapy advancing clinical trials in the U.S. and China.